Lung Cancer Paradigms May Shift as New Data Emerge
By Trista Morrison
Monday, February 16, 2009
Despite the fact that lung cancer is both the highest frequency cancer in terms of incidence and the deadliest cancer in terms of estimated annual mortality rates (see Editor's note), few biotech options have successfully tapped into this massive market.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.